Cargando…

A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma

INTRODUCTION: Immune checkpoint inhibitors such as programmed cell death/−ligand 1 inhibitor and cytotoxic T‐lymphocyte‐associated antigen‐4 inhibitors have been widely used for various advanced malignancies. The mechanism of action for these inhibitors is the improvement of antitumor immunity via T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukiishi, Yousuke, Fukuhara, Hideo, Kurano, Yoshitaka, Shugimoto, Hiroki, Yamashita, Erika, Karasima, Takashi, Inoue, Keiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978067/ https://www.ncbi.nlm.nih.gov/pubmed/36874988 http://dx.doi.org/10.1002/iju5.12568

Ejemplares similares

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma
por: Tomioka-Inagawa, Risa, et al.
Publicado: (2022)

Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy
por: Gaffuri, P., et al.
Publicado: (2019)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

A case of mixed tumor formed by metastasis of urothelial carcinoma and malignant lymphoma to the same lymph nodes
por: Kobayashi, Shu, et al.
Publicado: (2021)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022)

Current status of photodynamic technology for urothelial cancer
por: Inoue, Keiji, et al.
Publicado: (2021)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
por: Ishii, Akiko, et al.
Publicado: (2020)

Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
por: Crist, Michael, et al.
Publicado: (2019)

A CASE OF RAPIDLY PROGRESSIVE RETINOPATHY ASSOCIATED WITH PEMBROLIZUMAB IMMUNOTHERAPY FOR METASTATIC UROTHELIAL CARCINOMA
por: Sakai, Daiki, et al.
Publicado: (2023)

Unusual severe gastritis and gastric ulcers caused by pembrolizumab
por: Liu, WT, et al.
Publicado: (2022)

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
por: Liu, Yung-Hao, et al.
Publicado: (2021)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
por: Shimizu, Takuto, et al.
Publicado: (2022)

Well-differentiated liposarcoma of the spermatic cord: A case report
por: Shiba, Yuhei, et al.
Publicado: (2021)

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
por: Rijnders, Maud, et al.
Publicado: (2022)

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma
por: Hamada, Kazuki, et al.
Publicado: (2023)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma
por: Xu, Zhenying, et al.
Publicado: (2022)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

Severe gastritis due to pembrolizumab treatment in a lung cancer patient
por: Hayama, Noriko, et al.
Publicado: (2020)

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
por: Ito, Katsuhiro, et al.
Publicado: (2022)

Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
por: Yamada, Toyohiro, et al.
Publicado: (2022)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis
por: Yanagisawa, Takafumi, et al.
Publicado: (2021)

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
por: Zan, Ning, et al.
Publicado: (2022)

Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan
por: Fujiwara, Motohiro, et al.
Publicado: (2021)

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
por: McNally, Michelle A., et al.
Publicado: (2021)

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
por: Kobayashi, Takashi, et al.
Publicado: (2020)

Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
por: Taguchi, Satoru, et al.
Publicado: (2021)

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
por: Truong, Phu, et al.
Publicado: (2016)

Metastatic urothelial carcinoma()()
por: Gómez-Moyano, Elisabeth, et al.
Publicado: (2021)

Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab
por: Alnajar, Hussein, et al.
Publicado: (2022)

Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma
por: Takeda, Hiroki, et al.
Publicado: (2021)

FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab
por: Kawashima, Atsunari, et al.
Publicado: (2021)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab – Differences and Similarities in Comparison to “endogenous” autoimmune Type A Gastritis and a review of literature
por: Ecker, Miriam Eva, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tk2kuisp8pfplk8tke60ag6o6r